Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000511 | 0.97 | — | — | |
| SCHEMBL19047399 | 0.86 | — | — | |
| SCHEMBL3605682 | 0.76 | CES2 (0.39) | MGLLCES2CES1HDAC8HDAC6 | |
| SCHEMBL13652381 | 0.75 | GABRA1 (0.41) | TSHRNOS2 | |
| SCHEMBL23547192 | 0.74 | CES2 (0.38) | MGLLCES2CES1HDAC8HDAC6 | |
| SCHEMBL11210860 | 0.74 | CES2 (0.38) | MGLLCES2CES1HDAC8HDAC6 | |
| SCHEMBL11211286 | 0.74 | CES2 (0.38) | MGLLCES2CES1HDAC8HDAC6 | |
| SCHEMBL8464246 | 0.74 | CES2 (0.38) | MGLLCES2CES1HDAC8HDAC6 | |
| SCHEMBL951792 | 0.72 | CES2 (0.36) | MGLLCES2CES1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL29945534 | 0.72 | CES2 (0.36) | MGLLCES2CES1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007396-B1 | Enfumafungin derivatives as antifungal agents | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2346332-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | Medivation Technologies, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7863465-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| WO-2010051501-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-2007396-A1 | ANTIFUNGAL AGENTS | Merck and Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007127012-A1 | ANTIFUNGAL AGENTS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009504-A1 | Antifungal agents | DPM1, MAN2B1, MAN2A1 | MGLL 1627/4885CES2 3273/4885CES1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.